On February 14, 2025, the U.S. Food and Drug Administration (FDA) delivered a Valentine’s Day gift to patients battling symptomatic tenosynovial giant cell tumor (TGCT): the approval of vimseltinib (Romvimza), a novel kinase inhibitor developed by Deciphera Pharmaceuticals, LLC. This marks a significant milestone for adults with TGCT—a rare tumor affecting joints and tendons—especially in cases where surgery could worsen function or cause severe morbidity.
What is TGCT, and Why Does This Matter?
Tenosynovial giant cell tumor is an uncommon condition that can lead to pain, swelling, and restricted movement. For many patients, surgical removal is the go-to treatment, but when surgery risks further damage—like loss of joint function or serious complications—a non-surgical option becomes critical. That’s where vimseltinib steps in, offering a targeted therapy for adults facing this challenging diagnosis.
The MOTION Study: Proof in the Numbers
The FDA’s decision hinges on compelling evidence from the MOTION trial (NCT05059262), a double-blind, multicenter study. Researchers enrolled 123 patients with confirmed TGCT (lesions ≥2 cm, measurable by RECIST v1.1) and randomized them 2:1—83 received vimseltinib (30 mg twice weekly), while 40 got a placebo—for 24 weeks. After this blinded phase, all participants could access vimseltinib in an open-label extension.
The results? At week 25, the overall response rate (ORR) was an impressive 40% (95% CI: 29%, 51%) for the vimseltinib group, compared to 0% (95% CI: 0%, 9%) for placebo—a statistically significant difference (p < 0.0001). Even better, the median duration of response (DOR) wasn’t reached, with 85% of responders (28 out of 33) sustaining benefits for at least 6 months, and 58% (19 out of 33) for 9 months or more, based on 6 months of follow-up.
But it’s not just about shrinking tumors. Patients on vimseltinib reported meaningful improvements in active range of motion, physical functioning, and pain compared to the placebo group—outcomes that could transform daily life for those affected.
Safety and Dosage: What to Know
Vimseltinib isn’t without side effects, though. The most common reactions (affecting ≥20% of patients) include increased aspartate aminotransferase (AST), periorbital edema, fatigue, rash, elevated cholesterol, peripheral and facial edema, reduced neutrophils and leukocytes, itching (pruritus), and increased alanine aminotransferase (ALT). Healthcare providers will monitor these closely.
The recommended dose is straightforward: 30 mg taken orally twice weekly, with at least 72 hours between doses. Full prescribing details will soon be available on Drugs@FDA (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm).
Related Articles: